Cultural norms not unique to human societies
Humans are not alone in their desire to conform to cultural norms, according to new study findings that confirm, for the first time, chimpanzees share the same conformist tendencies. Researchers, in determining how chimpanzee communities share and maintain traditions, discovered they possess a natural motivation to copy their peers well into adulthood and say that although other species show some...
Neurogen Proprietary Insomnia Compound Data for Two Studies
Presented at Associated Professional Sleep Societies Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Jun 13, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced that data from previousPhase 1 and Phase 2a clinical studies for NG2-73, the Company'slead compound for the treatment of insomnia, were presented in twosessions at the SLEEP 2007 Annual Meeting of the AssociatedProfessional Sleep
Societies (APSS) in Minneapolis, Minnesota. TwoPhase 2b clinica...
Neurogen Proprietary Insomnia Compound Data Presented at Associated
Professional Sleep Societies Annual Meeting
BRANFORD, Conn.--(BUSINESS WIRE)--Jun 11, 2007 - NeurogenCorporation (Nasdaq: NRGN) today announced that data from previousPhase 1 clinical studies for NG2-73, the Company's lead compoundfor the treatment of insomnia, were presented today at the SLEEP2007 Annual Meeting of the Associated Professional Sleep
Societies(APSS) in Minneapolis, Minnesota. Two Phase 2b clinical studieswith NG2-73 i...
Opexa Presents Tovaxin Research at Federation of Clinical
Immunology Societies Annual Meeting
THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - OpexaTherapeutics, Inc. (NASDAQ:OPXA), a company involved in thedevelopment and commercialization of cell therapies, made a posterpresentation at the 2007 Annual Meeting of the Federation ofClinical Immunology
Societies (FOCIS) in San Diego June 7-11 at theSheraton San Diego Hotel & Marina. The poster, entitled"Identifying New Immuno...
Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the
Annual Meeting of the Associated Professional Sleep Societies
ROCKVILLE, Md., June 08, 2007 /PRNewswire-FirstCall/ -- VandaPharmaceuticals Inc. announced today that Dr. Tom Roth, Director ofthe Henry Ford Sleep Disorders and Research Center in Detroit, MI,will deliver an oral presentation on recent Phase III clinicaltrial results for VEC-162, Vanda's balanced melatonin (MT1/MT2)receptor agonist, at SLEEP 2007, the 21st annual meeting of theAssociat...
Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric
Academic Societies' Annual Meeting
Surfaxin Phase 2 BPD Clinical Data Selected and Presented asPlatform Presentation Aerosurf Utilizing Chrysalis Aerosol-Generator TechnologyDemonstrates Optimal Functional Activity WARRINGTON, Pa., May 8, 2007 (PRIME NEWSWIRE) -- DiscoveryLaboratories, Inc. (Nasdaq:DSCO) announced that results from itspreviously completed Phase 2 clinical trial of Surfaxin(r)(lucinactant intr...
More>>